A cross-sectional study analyzing publicly available Medicare Part D appeals reveals 61% of denials for anticancer medications due to failure to meet prior-authorization criteria were overturned, highlighting that streamlining approval for on-label therapy is a good opportunity to reduce administrative barriers to cancer care. | Kwon, JAMA Netw Open 2026
